[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rijnstate Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":204},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,73,103,131,155,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100476452","comparison-of-evar-and-esar-for-infrarenal-aortic-aneurysms-with-a-wide-proximal-neck-100476452",false,"NCT05484115","Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck","Randomized Controlled Clinical Trial on the Application of Heli-FX EndoAnchors in Conjunction With the Endurant II\u002FIIs Endograft in Infrarenal Aortic Aneurysms With a Wide Infrarenal Neck (HERCULES Trial)","HERCULES","Inclusion Criteria:\n\n* Age 18 years or older\n* Provided written informed consent\n* Clinical necessity for treatment of the AAA, according to the current guidelines in the geographies participating\n* Elective repair\n* Eligible anatomy for treatment with the Endurant II\u002FIIs stent graft system and Heli-FX EndoAnchor system according to the IFU of both devices\n* Infrarenal neck diameter ≥ 28 mm and ≤32 mm\n* Proximal neck length ≥10mm\n\nExclusion Criteria:\n\n* Anatomy outside the IFU of the ndurant II\u002FIIs stent graft system and Heli-FX EndoAnchor system\n* Planned use of AUI main body device\n* Patient is participating in another clinical study, potentially conflicting with the outcomes of the current study.\n* Patient with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2 before the intervention\n* Patient's life expectancy \\\u003C2 years as judged by the investigator\n* Patient has a psychiatric or other condition that may interfere with the study\n* Patient has a known allergy to any device component\n* Patients with a systemic infection who may be at increased risk of endovascular graft infection.\n* Patient has a coagulopathy or uncontrolled bleeding disorder\n* Patient has a ruptured, leaking, or mycotic aneurysm\n* Patient is not eligible for standard EVAR\n* Patient had a Cerebro Vascular Accident (CVA) or a myocardial infarction (MI) within the prior three months\n* Patient is pregnant (Female patients of childbearing potential only)\n* Patient has active COVID-19 infection or has been diagnosed with long COVID-19 requiring hospitalization within the 6 months prior to procedure.\n* Patient has previously been treated with stent grafts in the aorto-iliac arteries","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The HERCULES trial is a Randomized controlled clinical trial designed to prospectively compare endosuture aneurysm repair (ESAR) to standard endovascular aneurysm repair (EVAR) clinical outcomes in treatment of infrarenal abdominal aortic aneurysm (AAA) in subjects having wide proximal aortic neck diameters (≥ 28mm and ≤ 32mm).",[27],"Aortic Aneurysm, Abdominal",[29,30,31,32,33,34,35,36,37],"AAA","Endovascular treatment","Wide proximal neck","EndoAnchors","Infrarenal","EVAR (Endovascular aneurysm repair)","ESAR (Endosuture aneurysm repair)","Endurant II\u002FIIs stent graft system","Heli-FX EndoAnchor system","RECRUITING","2026-05-08",{"date":41,"type":42},"2026-05-11","ACTUAL",{"date":44,"type":42},"2023-05-26",{"date":46,"type":21},"2033-04",{"name":48,"class":49},"Rijnstate Hospital","OTHER",36,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100598368","impact-of-aorto-iliac-occlusive-disease-treatment-on-blood-pressure-100598368","NCT07070583","Impact of Aorto-Iliac Occlusive Disease Treatment on Blood Pressure","Impact of Endovascular Treatment of Aorto-iliac Disease on Systemic Hypertension A Pilot Study Impact of Aorto-Iliac Occlusive Disease Treatment on Blood Pressure","Inclusion Criteria:\n\n* Age ≥18 years\n* Singed informed consent\n* Chronic occlusion in the infrarenal aorta and\u002For one or both common iliac arteries\n* Total lesion length of ≥30mm\n* Clinical indication for treatment of the pathology (Chronic limb threatening ischemia or disabling intermittent claudication not responding to supervised exercise training)\n\nExclusion Criteria:\n\n* Patient is unable to understand the study requirements and\u002F or is unwilling to adhere to the follow-up\n* Juxtarenal pathology (\\\u003C2cm below the lowest renal artery)\n* Acute occlusion of the target area (Acute Leriche Syndrome)\n* Embolic disease",{"count":59,"type":21},20,[24],"Hypertension is a major risk factor for a variety of cardiovascular diseases. When hypertension results from increased vascular resistance due to a narrowing of the descending aorta, it can be effectively treated with stenting. More recently, evidence suggest that stenting in more distal parts of the arterial vascular bed is also associated with a reduction in blood pressure. The investigators hypothesize that stenting of occlusions more distal of the descending aorta decreases the central blood pressure and afterload as reflected by NT-proBNP (N-terminal pro-Brain Natriuretic Peptide), a biomarker of intracardiac pressures and predictor of heart failure events. The goal of this pilot study is to prospectively investigate changes in blood pressure after stent placement in the aorto-iliac region.",[63,64],"Aorto Iliac Occlusive Disease","Blood Pressure","2026-03-30",{"date":67,"type":42},"2026-04-03",{"date":65,"type":42},{"date":70,"type":21},"2027-12-31",{"name":48,"class":49},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100616345","evaluation-of-effectiveness-of-closed-loop-spinal-cord-stimulation-cl-scs-therapy-for-treatment-of-chemotherapy-induced-peripheral-neuropathy-100616345","NCT07304401","Evaluation of Effectiveness of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy for Treatment of Chemotherapy Induced Peripheral Neuropathy","Assessment of Effectiveness of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy on Pain Reduction and Improvement of Quality of Life in Patients With Chemotherapy Induced Peripheral Neuropathy","CIPRESS","* Subject is deemed a suitable candidate for SCS implantation and has been routinely scheduled to undergo an SCS implantation with the Evoke SCS System.\n* Subject has a minimum of leg or arm pain intensity of 5\u002F10 on the numeric rating scale (NRS) at baseline due to CIPN.\n* Patients with CIPN following chemotherapy and at least 6 months post-treatment\n* CIPN symptoms for a minimum duration of 3 months.\n* Patient deemed to be in remission per discretion of treating oncologist\n* No existing contraindications for SCS\n* Subject is ≥ 18 years old.\n* Subject is not pregnant or nursing.\n* Subject is willing and capable of giving informed consent.\n* No satisfactory treatment effect with anti-neuropathic medication or intolerable side-effects\n* No satisfactory treatment effect with minimal invasive pain treatments (including ketamine or lidocaine infusion therapy)\n\nExclusion Criteria:\n\n* Patient refusal to be included in study\n* Patients unwilling or mentally incapable to complete the study questionnaires\n* Other causes of neuropathy (for example diabetic- or small fiber neuropathy)\n* Previous treatment with SCS for CIPN\n* Presence of another pain syndrome unrelated to CIPN\n* History of lower limb amputation or ulceration\n* Body mass index (BMI) ≥ 40\n* Severe psychiatric or neurological disorders\n* Any other contra indication for locoregional anaesthesia",{"count":59,"type":21},"OBSERVATIONAL","The goal of this observational study is to learn about the effectiveness of closed-loop spinal cord stimulation (CL-SCS) therapy for treatment of painful chemotherapy induced peripheral neuropathy.\n\nThe closed-loop SCS (CL-SCS) system stimulates the nerves in the spinal cord, measures their responses and automatically adjust the stimulation level accordingly in real time for each delivered pulse.",[85,86],"Chemotherapy Induced Peripheral Neuropathy (CIPN)","Neuropathic Pain",[88,89,90,91,92,93],"CIPN","Chemotherapy induced peripheral neuropathy","Spinal Cord Stimulation","SCS","Closed-Loop","neuropathic pain","2025-12-24",{"date":96,"type":42},"2025-12-26",{"date":98,"type":21},"2025-12-01",{"date":100,"type":21},"2028-12-01",{"name":48,"class":49},5,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100579685","blood-flow-evaluation-after-carotid-surgical-treatment-100579685","NCT06827509","Blood Flow Evaluation After Carotid Surgical Treatment","Blood Flow Evaluation After Carotid Surgical Treatment: Carotid Endarterectomy With Patch Repair Versus Eversion Technique","BEAT","Inclusion Criteria:\n\n* Presence of carotid artery stenosis (≥50%) according to conventional clinically performed imaging (duplex\u002FCT(A)\u002FMR(A)) for which patient underwent uncomplicated CEA with either a patch plasty or the eversion technique\n* ≥18 years old;\n* Able to provide signed or oral informed consent\n* Carotid artery \\\u003C25mm below skin\n\nExclusion Criteria:\n\n* Carotid bifurcation with depth of center bulb lumen ≥2.5cm\n* Restenosis after carotid revascularisation at side of interest\n* Participating in another clinical study, interfering on outcomes",{"count":112,"type":21},40,"Approximately 20% of strokes originate from the rupture of an atherosclerotic plaque in the carotid artery. Surgical revascularization, i.e. carotid endarterectomy (CEA), is the treatment of choice for patients with a symptomatic carotid stenosis each year about 3,000 procedures are performed in the Netherlands. Currently, two surgical procedures are performed in clinical practice. Most frequently an endarterectomy is performed using a length incision over the artery, followed by a patch plasty (CEAP), in order to reduce the risk of restenosis. As an alternative the eversion technique (ET) was introduced, in which transversal arteriotomy is performed and the plaque is removed from within. After reconstruction with a patch a \\>50% restenosis has been described in 6-36% of patients during long-term follow-up. When using the eversion technique this is seen in 1.7-2.5%, while also the risk on adverse events seem to be lower. One of the drivers for atherosclerosis in general is a disturbance of local blood flow. This may lead to turbulence, recirculation and stasis of blood. The subsequent low Wall Shear Stress may lead to the ne formation of plaque that in turn may become instable and cause recurrent ischemic events. Recently, a breakthrough was achieved in the imaging options of flow in the carotid arteries, using Vector Flow Imaging. Using a fully programmable ultrasound machine, over 10,000 frames per second can be captured, in comparison to about 50 in regular ultrasound. This enables the tracking of particles that, after processing will provide the needed flow information. A recent study, comparing flow before and after CEAP has shown that there is significant recirculation after reconstruction. This raises the question whether this would be more optimal after ET, which would support the potential lower incidence of recurrent stenosis.",[115],"Carotid Endarterectomy",[117,118,119,120,121],"Ultrafast ultrasound flow imaging","Velocity vector imaging","Carotid endarterectomy","Patch repair","Eversion technique","NOT_YET_RECRUITING","2025-08-04",{"date":125,"type":42},"2025-08-05",{"date":127,"type":21},"2025-09-01",{"date":129,"type":21},"2026-04-01",{"name":48,"class":49},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":5},"100376584","tonometry1-and-duplex-ultrasound2-to-predict-cv-events-in-to-be-treated-patients-with-an-aaa-100376584","NCT04183426","Tonometry(1) and Duplex Ultrasound(2) to Predict CV Events in to be Treated Patients With an AAA","Tonometry(1) and Duplex Ultrasound(2) to Predict Cardiovascular Events in to be Treated Patients With an Abdominal Aortic Aneurysm (One-Two-Treat Trial)","One-Two-Treat","Inclusion Criteria:\n\n* Male or female at least 18 years old;\n* Informed consent form understood and signed and patient agrees to follow- up visits;\n* Has an infrarenal or juxtarenal abdominal aortic aneurysm (AAA), scheduled for elective repair (i.e open repair, EVAR, FEVAR and CHEVAR) according to standard practice;\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C 2 years;\n* Psychiatric or other condition that may interfere with the study;\n* Participating in another clinical study, interfering on outcomes;\n* Increased risk for coronary spasms (score Rose-questionnaire ≥2;\n* Presence of Raynaud's phenomenon, Marfan syndrome, chronic pain syndrome at upper extremity(s), presence of an AV fistula or shunt, open wounds to the upper extremity(s), and\u002For scleroderma associated with placing the hand in ice water;\n* Recent (\\\u003C3 months) presence of angina pectoris, myocardial infarction, cerebral infarction, and\u002For heart failure, or PAD treatment.",{"count":140,"type":21},194,"Abdominal aortic aneurysm (AAA) is a common vascular disease and associated with risk of rupture, but also with a high cardiovascular (CV) event rate. A key difficulty in AAA is predicting these life-threatening complications, which are strongly linked to vascular health. In 2013, the SMART risk score was developed to calculate the risk of the patients for recurrent vascular events based on clinical characteristics. Recently, a novel, easy to perform, non-invasive test of endothelial function (the carotid artery reactivity (CAR) test), reflecting target organ damage, has been introduced. The CAR is a simple, quick (5-min), non-invasive test that uses ultrasound to examine the carotid artery in response to sympathetic stimulation by placing one hand in cold water. This test shows strong agreement with both coronary and aortic responses to sympathetic stimulation and predicted CV-events in patients with peripheral arterial disease.\n\nThe aim of this prospective 2-year follow-up study is to investigate the predictive capacity of the CAR-test for development of CV-events after elective AAA repair in comparison to the SMART risk score. Secondary objectives are to investigate the predictive capacity of arterial stiffness measurements and the post-operative CAR-test for development of CV-events and to evaluate health status scores to provide insight if these scores can support clinical decision making.",[143,144],"Abdominal Aortic Aneurysm","Cardiovascular Events",[146,143,144],"Functional Response","2025-03-03",{"date":149,"type":42},"2025-03-06",{"date":151,"type":42},"2020-06-12",{"date":153,"type":21},"2027-06",{"name":48,"class":49},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},"100471622","effects-of-active-versus-passive-recharge-burst-spinal-cord-stimulation-on-pain-experience-in-persistent-spinal-pain-syndrome-type-2-a-multicenter-randomized-trial-burst-rap-study-100471622","NCT05421273","Effects of Active Versus Passive Recharge Burst Spinal Cord Stimulation on Pain Experience in Persistent Spinal Pain Syndrome Type 2: a Multicenter Randomized Trial (BURST-RAP Study)","BURST-RAP","Inclusion Criteria:\n\n* Subjects between 18 and 70 years of age\n* At least moderate level of catastrophizing as measured with the Pain catastrophizing scale (PCS) of at least 20 at first visit of the pain clinic.\n* Chronic pain diagnoses as PSPS Type 2 of at least 6 months\n* Neurologic exam without marked motor deficit.\n* LBP and\u002For leg pain intensity should be 5 or higher measured with the 11-box NRS 0-10\n* Meets all the inclusion criteria for the implantation of a neurostimulation system as typically utilized in the study center. PM: depression is not an exclusion criteria\n* Subject has been screened by a multi-disciplinary panel including a psychologist and deemed suitable for implantation\n* Subject is able and willing to comply with the follow-up schedule and protocol\n* Subject is able to provide written informed consent\n\nExclusion Criteria:\n\n* Female subject of childbearing potential is pregnant\u002Fnursing or plans to become pregnant during the course of the study\n* Escalating or changing pain condition within the past month as evidenced by investigator examination\n* BMI ≥35\n* \"Subject has had injection therapy or radiofrequency treatment for their low back pain (LBP) or leg pain within the past 3 months\"\n* Subject currently has an active implantable device including ICD, pacemaker, spinal cord stimulator or intrathecal drug pump\n* Subject is unable to operate the device\n* Severe spinal column degeneration likely to cause technical problems with neuromodulation, to be assessed by the treating physician\n* Previous Neurostimulation therapy","70 Years",{"count":164,"type":21},96,[24],"Spinal cord stimulation (SCS) has shown to be an effective treatment for patients with persistent spinal pain syndrome Type 2 (PSPS Type 2). The method used to deliver electrical charge in SCS is important. One such method is burst stimulation. Two variations of burst waveforms are currently in use: one that employs active recharge and one that uses passive recharge. It is still unknown if there are clinical differences between active recharge and passive recharge burst SCS. To date, no clinical studies have been performed that directly compared these two burst stimulation waveforms. The objective of this Randomized Clinical Trial (RCT) is to assess and compare effect of passive recharge burst SCS with active recharge burst SCS on pain relief and motivational-emotional facets of pain",[168,169],"Persistent Spinal Pain Syndrome Type 2","Failed Back Surgery Syndrome","2024-11-15",{"date":172,"type":42},"2024-11-19",{"date":174,"type":42},"2022-02-16",{"date":176,"type":21},"2026-06-30",{"name":48,"class":49},6,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":72},"100530273","phase-4-dutch-weight-control-in-atrial-fibrillation-study-100530273","NCT06184633","DUTCH Weight Control in Atrial Fibrillation Study","DUTCH Weight Control in Atrial Fibrillation Study, a Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Trial","DUTCH-WAIST","Inclusion Criteria:\n\n* Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -\n* Age ≥ 18\n* Obesity, as defined as:\n\n  * BMI ≥ 30 kg\u002Fm2, or\n  * BMI ≥27 kg\u002Fm2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)\n* Scheduled ECV\n* Written informed consent\n\nExclusion Criteria:\n\n* Permanent AF\n* Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery\n* Current or previous treatment with amiodaron\n* HbA1c ≥ 48 mmol\u002FL, \\\u003C3 months prior to randomization\n* History of diabetes mellitus type 1 or 2\n* Prior bariatric surgery\n* Use of other anti-obesity medication, \\\u003C3 months prior to enrollment\n* Contra-indication for, or prior use of a GLP1-receptor agonist\n* History of chronic pancreatitis or acute pancreatitis \\\u003C6 months\n* Acute coronary syndrome \\\u003C6 months\n* Severe (grade III) valvular disease\n* eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2\n* Heart failure NYHA class III-IV\n* Participation in another investigational drug or device study in the past 30 days (registry enrollment is allowed)\n* Any condition or therapy, which would make the participant unsuitable for the study (e.g. vulnerable, non-compliance) or life-expectancy \\\u003C12 months, as judged by the treating physician.\n* Female who is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.",{"count":188,"type":21},280,[190],"PHASE4","Quantify the effect of an innovative weight loss management on rhythm control.",[193,194,195],"Atrial Fibrillation","Obesity","Weight Loss","2024-09-09",{"date":198,"type":42},"2024-09-19",{"date":200,"type":42},"2024-07-21",{"date":202,"type":21},"2027-05-01",{"name":48,"class":49},""]